Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Experimental drugs and combination therapy

J K Seydel1, K J Schaper, S Rüsch-Gerdes

  • 1Institut für Experimentelle Biologie und Medizin, Borstel, Germany.

Immunobiology
|October 1, 1994
PubMed
Summary

New strategies are needed for tuberculosis (TB) drug development due to rising multiple drug resistance (MDR). Synergistic drug combinations, like hydrazones with rifampicin, show promise in overcoming resistance, with personalized treatment optimization showing encouraging clinical results.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multicentre study to establish interpretive criteria for clofazimine drug susceptibility testing.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2019
Same author

Ethambutol-resistance testing by mutation detection using MTBDRsl.

International journal of mycobacteriology·2017
Same author

First national survey of anti-tuberculosis drug resistance in Azerbaijan and risk factors analysis.

Public health action·2015
Same author

Inactivation of Mycobacterium bovis ssp. caprae in high-temperature, short-term pasteurized pilot-plant milk.

Journal of dairy science·2015
Same author

Cost of multi drug resistance tuberculosis in Germany.

Respiratory medicine·2014
Same author

Characterisation of pyrazinamide-resistant Mycobacterium tuberculosis strains isolated in Poland and Germany.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2014

Area of Science:

  • Microbiology
  • Pharmacology
  • Infectious Diseases

Background:

  • Tuberculosis (TB) incidence is rising globally.
  • Increasing multiple drug resistance (MDR) and primary resistance in Mycobacterium avium necessitate novel therapeutic strategies.
  • Changes in mycobacterial cell wall construction, including synthesis of multilamellar components within macrophages, contribute to drug resistance by limiting drug penetration.

Purpose of the Study:

  • To explore new strategies for overcoming MDR in tuberculosis.
  • To investigate the potential of synergistic drug combinations to enhance therapeutic efficacy.
  • To develop and evaluate an optimization procedure for personalized TB treatment.

Main Methods:

  • Analysis of factors contributing to MDR, focusing on cell wall alterations.

Related Experiment Videos

  • Evaluation of drug permeation properties and lipophilicity in relation to efficacy.
  • Testing of synergistic drug combinations, including novel hydrazones, thiacetazone, and rifampicin.
  • Assessment of antagonistic drug interactions (e.g., clofazimine-dapsone, ofloxacin-rifampicin).
  • Development of an optimization procedure based on patient-derived mycobacterial resistance profiling.

    • Main Results:

    • More lipophilic drug derivatives within a class demonstrated higher efficacy.
    • Highly synergistic combinations, such as hydrazones/thiacetazone with rifampicin, were identified.
    • Antagonistic interactions were observed for clofazimine-dapsone and ofloxacin-rifampicin combinations.
    • The developed optimization procedure allows for individualized treatment strategies.

    Conclusions:

    • Improving drug permeation and developing synergistic combinations are key to overcoming MDR-TB.
    • Careful selection of drug combinations is crucial to avoid antagonism and maximize therapeutic benefit.
    • Personalized treatment optimization based on specific resistance patterns holds promise for effective TB therapy, with preliminary clinical data being encouraging.